Unknown

Dataset Information

0

Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.


ABSTRACT: The 4-component vaccine 4CMenB, developed against invasive disease caused by meningococcal serogroup B, is approved for use in infants in several countries worldwide. 4CMenB is mostly used as 3 + 1 schedule, except for the UK, where a 2 + 1 schedule is used, and where the vaccine showed an effectiveness of 82.9%. Here we compared the coverage of two 4CMenB vaccination schedules (3 + 1 [2.5, 3.5, 5, 11 months] versus 2 + 1 [3.5, 5, 11 months of age]) against 40 serogroup B strains, representative of epidemiologically-relevant isolates circulating in England and Wales in 2007-2008, using sera from a previous phase 3b clinical trial. The strains were tested using hSBA on pooled sera of infants, collected at one month post-primary and booster vaccination. 4CMenB coverage was defined as the percentage of strains with positive killing (hSBA titres ? 4 after immunisation and negative baseline hSBA titres < 2). Coverage of 4CMenB was 40.0% (95% confidence interval [CI]: 24.9-56.7) and 87.5% (95%CI: 73.2-95.8) at one month post-primary and booster vaccination, respectively, regardless of immunisation schedule. Using a more conservative threshold (post-immunisation hSBA titres ? 8; baseline ? 2), at one month post-booster dose, strain coverages were 80% (3 + 1) and 70% (2 + 1). We used a linear regression model to assess correlation between post-immunisation hSBA data for each strain in the two groups; Pearson's correlation coefficients were 0.93 and 0.99 at one month post-primary and booster vaccination. Overall, there is no evidence for a difference in strain coverage when 4CMenB is administered according to a 3 + 1 or 2 + 1 infant vaccination schedule.

SUBMITTER: Biolchi A 

PROVIDER: S-EPMC6605712 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.

Biolchi Alessia A   Tomei Sara S   Santini Laura L   Welsch Jo Anne JA   Toneatto Daniela D   Gaitatzis Nikolaos N   Bai Xilian X   Borrow Ray R   Giuliani Marzia Monica MM   Mori Elena E   Pizza Mariagrazia M  

Human vaccines & immunotherapeutics 20190102 3


The 4-component vaccine 4CMenB, developed against invasive disease caused by meningococcal serogroup B, is approved for use in infants in several countries worldwide. 4CMenB is mostly used as 3 + 1 schedule, except for the UK, where a 2 + 1 schedule is used, and where the vaccine showed an effectiveness of 82.9%. Here we compared the coverage of two 4CMenB vaccination schedules (3 + 1 [2.5, 3.5, 5, 11 months] versus 2 + 1 [3.5, 5, 11 months of age]) against 40 serogroup B strains, representative  ...[more]

Similar Datasets

| S-EPMC4186018 | biostudies-literature
| S-EPMC5411059 | biostudies-literature
| S-EPMC4018652 | biostudies-literature
| S-EPMC3360877 | biostudies-literature
| S-EPMC3890039 | biostudies-literature
| S-EPMC4780694 | biostudies-literature
| S-EPMC11338074 | biostudies-literature
| S-EPMC7954916 | biostudies-literature
| S-EPMC5349334 | biostudies-literature
| S-EPMC7056808 | biostudies-literature